TD Cowen assumed coverage on shares of Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat reports. The brokerage set a “buy” rating on the stock.
ORKA has been the topic of several other reports. Jefferies Financial Group began coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They set a “buy” rating and a $40.00 target price on the stock. Wedbush began coverage on shares of Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $41.25.
Read Our Latest Research Report on ORKA
Oruka Therapeutics Stock Performance
Oruka Therapeutics Company Profile
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
Recommended Stories
- Five stocks we like better than Oruka Therapeutics
- How to buy stock: A step-by-step guide for beginners
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- What Investors Need to Know to Beat the Market
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.